Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.

\* Inclusion Criteria: \[Time of screening\] * Patients who have transplanted in primary living donor liver in 35 days or who plan to be transplanted in primary living donor liver. * Over 20 years old(male or female) * Agreement with written informed consent \[Time of randomization\] - Patients who have transplanted liver within 4 weeks(25 days to 35 days) \* Exclusion Criteria \[Time of screening\] * Patients who have transplanted non-liver organs or have plan to be transplanted non-liver organs. * Patients with bioartificial liver (cell system) * Patients who diagnosed with malignant tumor within 5 years \[however, who have recovered from skin cancer (squamous cell/basal cell carcinoma) or thyroid cancer, hepatocellular carcinoma without main vessel invasion or extrahepatic metastasis can be enrolled\] * Patients with severe systemic infection * Women who are pregnant or breast feeding or not agree to the proper use of contraception during the trial * Participated in other trial within 4 weeks * In investigator's judgement \[Time of randomization\] * Patients with acute rejection who have been clinically treated after liver transplantation. * Patients with complication related to the hepatic artery such as hepatic artery thrombosis at the time of randomization. * At screening * WBC \<1,500/mm\^3 or PLT \<30,000/mm\^3 or over 3 times upper than normal range of liver function tests(T-bilirubin, AST, ALT) levels * Protein/Creatinine ratio(urine test) \> 1 or eGFR by MDRD\< 30mL/min/1.73m\^2 or Total cholesterol \> 350mg/dL or triglycerides \> 500mg/dL * Patients taking HCV(hepatitis C virus) Therapeutic Drugs * Patients who had plasmapheresis within 1 week. * Patents who had a record of taking mTOR inhibitor before. * In investigator's judgement